DAFTAR PUSTAKA - Institutional Repository Undip (Undip …eprints.undip.ac.id/50731/8/Mutiara_Chairsabella_22010112130070... · 26. Antono D, Hamonangani R. Penyakit Arteri Perifer.

63

DAFTAR PUSTAKA

1. World Health Organization. Global status report on noncommunicable diseases

2014. Geneva: World Health Organization; 2014.

2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A

comparative risk assessment of burden of disease and injury attributable to 67

risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic

analysis for the Global Burden of Disease Study 2010. Lancet.

2012;380(9859):2224–60.

3. World Health Statistics. Causes of death 2008 : data sources and methods.

World Health. 2011;2010(September 2010):1–28.

4. Cardiovascular disease risk factors - Hypertension [Internet]. World Heart

Federation. [cited 2016 Jan 17]. Available from: http://www.world-heart-

federation.org/cardiovascular-health/cardiovascular-disease-risk-

factors/hypertension/

5. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N

Engl J Med. 2005;352(16):1685–95.

6. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et

al. General cardiovascular risk profile for use in primary care: the Framingham

Heart Study. Circulation. 2008 Feb 12;117(6):743–53.

7. Bouhanick B, Barbosa SLS, Marre M. Hypertension and diabetes. Arch Mal

Coeur Vaiss. 2000;93(11, S):1429–34.

8. IDF Diabetes ATLAS. 7th ed. Brussels: International Diabetes Federation;

2015. 12-7 p.

9. WHO | Diabetes [Internet]. World Health Organization; [cited 2015 Nov 23].

Available from: http://www.who.int/mediacentre/factsheets/fs312/en/

10. American Heart Association. Cardiovascular Disease & Diabetes [Internet].

[cited 2015 Nov 23]. Available from:

http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/

Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp/#.VlJnCtLhDIV

63

64

11. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al.

European Guidelines on Cardiovascular Disease Prevention in Clinical

Practice. The Fifth Joint Task Force of the European Society of Cardiology and

Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur

Heart J. 2012;33(13):1635–701.

12. Hong YM. Atherosclerotic cardiovascular disease beginning in childhood.

Korean Circ J. 2010;40(1):1–9.

13. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr.

SK. Carotid-artery intima and media thickness as a risk factor for myocardial

infarction and stroke in older adults. Cardiovascular Health Study

Collaborative Research Group. N Engl J Med. 1999;340(1):14–22.

14. Gómez-Marcos MA, Recio-Rodríguez JI, Rodríguez-Sánchez E, Patino-

Alonso MC, Magallón-Botaya R, Martínez-Vizcaino V, et al. Carotid Intima-

Media Thickness in Diabetics and Hypertensive Patients. Rev Española Cardiol

(English Ed. Elsevier; 2011 Jul 1;64(7):622–5.

15. Alatab S, Fakhrzadeh H, Sharifi F, Mostashfi A, Mirarefin M, Badamchizadeh

Z, et al. Impact of hypertension on various markers of subclinical

atherosclerosis in early type 2 diabetes. J Diabetes Metab Disord.

2014;13(1):24.

16. Marieb EN, Hoehn K. Human Anatomy & Physiology. 7th ed. San Francisco:

Benjamin Cummings; 2006.

17. Mescher AL. Junqueiras’s Basic Histology: Text and Atlas. 13th ed. New

York: McGraw-Hill Education; 2013. 217-24 p.

18. Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 9th ed.

Philadelphia: Elsevier Saunders; 2013. 335-43 p.

19. Libby P. The Pathogenesis, Prevention, and Treatment of Atherosclerosis. In:

Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors.

Harrison’s Principles of Internal Medicine. 19th ed. McGraw-Hill Education;

2015. p. 291e1–10.

20. Steinl DC, Kaufmann BA. Ultrasound imaging for risk assessment in

atherosclerosis. Int J Mol Sci. Multidisciplinary Digital Publishing Institute;

65

2015 Jan 29;16(5):9749–69.

21. Sherwood L. Fisiologi Manusia: dari Sel ke Sistem. 6th ed. Jakarta: Penerbit

Buku Kedokteran EGC; 2012.

22. Finn A V, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of

vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol. 2010 Jul

1;30(7):1282–92.

23. Antman EM, Loscalzo J. Ischemic Heart Disease. In: Kasper DL, Hauser SL,

Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of

Internal Medicine. 19th ed. McGraw-Hill Education; 2015. p. 1578–92.

24. Coronary Artery Disease [Internet]. National Library of Medicine; [cited 2016

Jan 9]. Available from:

https://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html

25. Coronary Artery Disease - Coronary Heart Disease [Internet]. [cited 2016 Jan

9]. Available from:

http://www.heart.org/HEARTORG/Conditions/More/MyHeartandStrokeNews/

Coronary-Artery-Disease---Coronary-Heart-

Disease_UCM_436416_Article.jsp#.VpENI7aLTIU

26. Antono D, Hamonangani R. Penyakit Arteri Perifer. In: Setiati S, Idrus A,

Sudoyo A w, Simadibrata K. M, Setiyohadi B, Syam AF, editors. Buku Ajar

Ilmu Penyakit Dalam. 6th ed. Jakarta: InternaPublishing; 2014. p. 1518–28.

27. Ropper AH, Samuels MA. Cerebrovascular Disease. In: Adams and Victor’s

Principle of Neurology. 9th ed. New York: McGraw-Hill; 2009. p. 746.

28. Ischemic Stroke | Internet Stroke Center [Internet]. [cited 2016 Jan 17].

Available from: http://www.strokecenter.org/patients/about-stroke/ischemic-

stroke/

29. History of the Framingham Heart Study [Internet]. [cited 2016 Jan 8].

Available from: https://www.framinghamheartstudy.org/about-fhs/history.php

30. Hackam DG, Anand SS. Emerging Risk Factors for Atherosclerotic Vascular

Disease: A Critical Review of the Evidenc. JAMA. 2003;290(7):932–40.

31. Strom JB, Libby P. Atherosclerosis. In: Lily L, editor. Pathophysiology of

Heart Disease. 5th ed. Walter Kluwer; 2011. p. 113–4.

66

32. Adi PR. Pencegahan dan Penatalaksanaan Aterosklerosis. In: Setiati S, Alwi I,

Sudoyo AW, Setiyohadi B, Sumandibrata K M, Syam AF, editors. Buku Ajar


33. Grundy SM, Cleeman JI, Merz CNB, Brewer HB, Luther T, Hunninghake

DB, et al. Implications of Recent Clinical Trials for the Natinal Cholesterol

Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb

Vasc Biol. 2004;24:e149–61.

34. European Society of Hypertension - European Society of Cardiology

Guidelines Committee. European Society of Hypertension - European Society

of Cardiology Guidelines for The Management of Arterial Hypertension. J

Hypertens. 2003;21(1011):53.

35. Chobanian A V., Bakris GL, Black HR, Cushman WC, Green L a., Izzo JL, et

al. Seventh report of the Joint National Committee on Prevention, Detection,

Evaluation, and Treatment of High Blood Pressure. Hypertension.

2003;42(6):1206–52.

36. Kementrian Kesehatan RI. Infodatin Hipertensi. Jakarta; 2014.

37. Tedjasukmana P. Tata Laksana Hipertensi. Cdk-192. 2012;39(4):251–5.

38. Alexander RW. Hypertension and the Pathogenesis of Atherosclerosis :

Oxidative Stress and the Mediation of Arterial Inflammatory Response: A New

Perspective. Hypertension. Lippincott Williams & Wilkins; 1995 Feb

1;25(2):155–61.

39. Purnamasari D. Diagnosis dan klasifikasi diabetes mellitus. In: Setiati S, Alwi

I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editors. Buku Ajar


40. Powers AC. Diabetes Mellitus: Complications. In: Kasper DL, Hauser SL,

Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of

Internal Medicine. 19th ed. McGraw-Hill Education; 2015. p. 2422–30.

41. Pedicino D, Giglio AF, Galiffa VA, Trotta F, Liuzzo G. Type 2 Diabetes,

Immunity and Cardiovascular Risk: A Complex Relationship. In: Oguntibeju

O, editor. Pathophysiology and Complications of Diabetes Mellitus. InTech;

2012.

67

42. Rask-madsen C, King GL. Review Vascular Complications of Diabetes :

Mechanisms of Injury and Protective Factors. Cell Metab. Elsevier Inc.;

2012;17(1):20–33.

43. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in Type 2 Diabetes :

Prevalence , Pathophysiology , and Management. Drugs. 2013;73:327–39.

44. Fodor G. Clinical Evidence Handbook: Primary Prevention of CVD: Treating

Dyslipidemia. Am Fam Physician. 2011;83(10):1207–8.

45. Adam JMF. Dislipidemia. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata K.

M, Setiyohadi B, Syam AF, editors. Buku Ajar Ilmu Penyakit Dalam. 6th ed.

Jakarta: InternaPublishing; 2014. p. 2551–60.

46. Executive Summary of The Third Report of The National Cholesterol

Education Program (NCEP) Expert Panel on Detection, Evaluation, And

Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

JAMA. 2001 May 16;285(19):2486–97.

47. Ballantyne CM, O’Keefe Jr. JH, Gotto Jr. AM. Dyslipidemia &

Atherosclerosis Essentials 2009. 4th ed. Jones & Bartlett Publishers; 2009.

48. Centers for Disease Control and Prevention, National Center for Chronic

Disease Prevention and Health Promotion, Office on Smoking and Health.

Cardiovascular Diseases. In: How Tobacco Smoke Causes Disease: The

Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of

the Surgeon General. Centers for Disease Control and Prevention (US); 2010.

49. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an

independent risk factor for cardiovascular disease: a 26- year follow-up of

participants in the Framingham Heart Study. Circulation. 1983 May

1;67(5):968–77.

50. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic

insights. Can J Cardiol. 2015 Feb;31(2):177–83.

51. Bowles DK, Laughlin MH. Mechanism of beneficial effects of physical

activity on atherosclerosis and coronary heart disease. J Appl Physiol.

2011;111(21):308–10.

52. Gray HH, Dawkins KD, Simpson IA, Morgan JM. Lecture Notes: Kardiologi.

68

5th ed. Wiley; 2008.

53. Vitale C, Miceli M, Rosano GMC. Gender-specific characteristics of

atherosclerosis in menopausal women: risk factors, clinical course and

strategies for prevention. Climacteric. 2007 Oct;10 Suppl 2:16–20.

54. Nasir K, Michos ED, Rumberger JA, Braunstein JB, Post WS, Budoff MJ, et

al. Coronary artery calcification and family history of premature coronary heart

disease: sibling history is more strongly associated than parental history.

Circulation. 2004 Oct 12;110(15):2150–6.

55. Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, et al.

Family history of premature coronary heart disease and coronary artery

calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation.

2007 Aug 7;116(6):619–26.

56. Michos ED, Vasamreddy CR, Becker DM, Yanek LR, Moy TF, Fishman EK,

et al. Women with a low Framingham risk score and a family history of

premature coronary heart disease have a high prevalence of subclinical

coronary atherosclerosis. Am Hear J. 2005 Dec;150(6):1276–81.

57. Fruchart J-C, Nierman MC, Stroes ESG, Kastelein JJP, Duriez P. New risk

factors for atherosclerosis and patient risk assessment. Circulation. 2004 Jun

15;109(23 Suppl 1):III15–9.

58. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial

thickness of the arterial wall: a direct measurement with ultrasound imaging.

Circulation. 1986. p. 1399–406.

59. de Groot E, van Leuven SI, Duivenvoorden R, Meuwese MC, Akdim F, Bots

ML, et al. Measurement of carotid intima–media thickness to assess

progression and regression of atherosclerosis. Nature. 2008;5(5):280–8.

60. Simova I. Intima-media thickness: Appropriate evaluation and proper

measurement, described. E-journal Cardiol Pract. 2015;13.

61. O’Leary DH, Bots ML. Imaging of atherosclerosis: carotid intima-media

thickness. Eur Heart J. 2010;31(14):1682–9.

62. Srámek A, Bosch JG, Reiber JH, Van Oostayen JA, Rosendaal FR. Ultrasound

assessment of atherosclerotic vessel wall changes: reproducibility of intima-

69

media thickness measurements in carotid and femoral arteries. Invest Radiol.

2000 Dec;35(12):699–706.

63. Touboul P-J, Labreuche J, Vicaut E, Belliard J-P, Cohen S, Kownator S, et al.

Country-based reference values and impact of cardiovascular risk factors on

carotid intima-media thickness in a French population: the “Paroi Artérielle et

Risque Cardio-Vasculaire” (PARC) Study. Cerebrovasc Dis. 2009

Jan;27(4):361–7.

64. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use

of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate

Cardiovascular Disease Risk: A Consensus Statement from the American

Society of Echocardiography Carotid Intima-Media Thickness Task Force

Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr.

2008;21(2):93–111.

65. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, B??hm M, et al.

2013 ESH/ESC guidelines for the management of arterial hypertension: The

Task Force for the management of arterial hypertension of the European

Society of Hypertension (ESH) and of the European Society of Cardiology

(ESC). Eur Heart J. 2013;34(28):2159–219.

66. Folkow B. Cardiovascular structural adaptation; its role in the initiation and

maintenance of primary hypertension. Clin Sci Mol Med Suppl. 1978;4:3s –

22s.

67. Gaballa MA, Jacob CT, Raya TE, Liu J, Simon B, Goldman S. Large Artery

Remodeling During Aging : Biaxial Passive and Active Stiffness.

Hypertension. 1998 Sep 1;32(3):437–43.

68. Tanaka H, Dinenno FA, Monahan KD, Desouza CA, Seals DR. Carotid artery

wall hypertrophy with age is related to local systolic blood pressure in healthy

men. Arter Thromb Vasc Biol. 2001;21(1):82–7.

69. Department of Chronic Diseases and Health Promotion. Global Physical

Activity Questionnaire. Geneva: World Health Organization; 2012. 1-8 p.

70. Kusumawardani RP. Kontribusi hipertensi terhadap aterosklerosis arteri

karotis interna pada pasien pasca stroke iskemik. Universitas Diponegoro;

70

2011.

71. Katakami N, Yamasaki Y, Ayaishi-Okano R, Ohtoshi K, Kaneto H, Matsuhisa

M, et al. Metformin or gliclazide, rather than glibenclamide, attenuate

progression of carotid intima-media thickness in subjects with type 2 diabetes.

Diabetologia. 2004;47:1906–13.

72. Stettler C, Allemann S, Ju P. Glycemic control and macrovascular disease in

types 1 and 2 diabetes mellitus : Meta-analysis of randomized trials. Am Hear

J. 2006;152(1):27–38.

73. Sutton-tyrrell K, Lassila HC, Meilahn E, Bunker C, Matthews KA, Kuller LH.

Carotid Atherosclerosis in Premenopausal and Postmenopausal Women and Its

Association With Risk Factors Measured After Menopause. Stroke.

1998;29(6):1116–21.

74. Im TS, Chun EJ, Lee MS, Adla T, Kim JA, Choi S Il. Grade-response

relationship between blood pressure and severity of coronary atherosclerosis in

asymptomatic adults : assessment with coronary CT angiography. Int J

Cardiovasc Imaging. 2014;30:105–12.

75. Darmawan A, Tugasworo D, Pemayun TGD. Hiperglikemia dan

Aterosklerosis Arteri Karotis Interna pada Penderita Pasca Stroke Iskemik. M

Med Indones. 2011;45(1):1–7.

76. Fromm A, Haaland ØA, Naess H, Thomassen L, Waje-andreassen U. Risk

factors and their impact on carotid intima-media thickness in young and

middle-aged ischemic stroke patients and controls : The Norwegian Stroke in

the Young Study. BMC. 2014;7(176):1–8.

77. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Prevalence of Comorbid

Hypertension and Dyslipidemia and Associated Cardiovascular Disease. Am J

Manag Care. 2004;10(12):926–32.

78. Mihardja L, Soetrisno U, Soegondo S. Prevalence and clinical profile of

diabetes mellitus in productive aged urban Indonesians. J Diabetes Investig.

2014;5(5):507–12.

79. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nature.

2009;5(3):150–9.

71

Lampiran 1.

PROSEDUR PENGUKURAN CIMT

1) Memposisikan pemeriksa dan pasien senyaman mungkin dimana pasien

terbaring pada tempat tidur dan pemeriksa duduk di samping kanan pasien.

2) Mengekstensikan leher dan memposisikan kepala pasien menoleh

kontralateral terhadap sisi leher yang akan diperiksa, kemudian mengoleskan

gel pada leher atau pada transduser.

3) Melakukan skrinning arteri karotis komunis menggunakan transduser dengan

orientasi transversal, dari proksimal hingga distal, sambil melihat layar

monitor hingga menemukan bulbus karotikus.

4) Memposisikan orientasi transduser menjadi longitudinal pada sisi lateral

arteri karotis kemudian merekam pencitraan pada monitor dalam bentuk

gambar diam.

5) Melakukan pengukuran CIMT pada dinding jauh pembuluh darah

menggunakan perangkat lunak pada alat.

6) Melakukan pemeriksaan dan pengukuran CIMT pada sisi leher yang lain

dengan cara yang sama.

7) Mengambil nilai rata – rata CIMT.

72

Lampiran 2. Ethical clearance

73

Lampiran 3. Surat izin melaksanakan penelitian

74

75

Lampiran 4. Informed cosent

76

77

Lampiran 5. Kuesioner

DAFTAR TILIK PENELUSURAN REKAM MEDIK DAN

WAWANCARA

No. CM :

Nama :

Jenis kelamin : Laki-laki Perempuan

Umur :

Pekerjaan :

Alamat :

No. HP :

Tinggi badan : _____cm Berat badan : _____ kg BMI : _____ kg/m2

Kontrol teratur/tidak : Ya Tidak

Status merokok : Ya Tidak

Data

Hipertensi

Tekanan darah

terakhir

Lama hipertensi Obat yang diminum

Data DM

Status DM : Ya Tidak

Anamnesis 3P + kadar GDS

Anamnesis 3P + kadar GDP

Lainnya (diagnosis dokter, mendapat terapi DM)

mg/dl

mg/dl

78

Kadar gula darah terakhir : GDP______mg/dl; GDS______ mg/dl

2PP ______mg/dl

Kadar HbA1c :

Lama DM :

Obat yang diminum :

Data dislipidemia

Status dislipidemia : Ya Tidak

Kadar kolesterol total : ________ mg/dl (dislipidemia: ≥240 mg/dl)

Kadar kolesterol LDL : ________ mg/dl (dislipidemia: ≥160 mg/dl)

Kadar kolesterol HDL : ________ mg/dl (dislipidemia: <40 mg/dl)

Kadar trigliserida : ________ mg/dl (dislipidemia: ≥200 mg/dl)

Lama dislipidemia :

Obat yang diminum :

Komplikasi/ penyakit lainnya

79

GLOBAL PHYSICAL ACTIVITY QUESTIONNAIRE (GPAQ)

Jenis Aktivitas Contoh Aktivitas

Aktivitas ringan Duduk, berdiri, mencuci piring, memasak, menyetrika, bermain

musik, menonton tv, mengemudikan kendaraan, berjalan perlahan

Aktivitas sedang Menyapu, mengepel, mencuci mobil, menanam tanaman, memanen

tanaman, menimba air, bersepeda pergi pulang beraktivitas,

Aktivitas berat Membawa barang berat, berkebun (menggali), bersepeda (16-

22km/jam), bermain sepak bola,

Olahraga sedang

Aerobik low-impact, berkuda, voli, berjalan sedang dan cepat,

bowling, golf, tenis meja, berenang, bersepeda, jogging, menari, tai

chi, yoga, kriket

Olahraga berat Sepak bola, basket, gym angkat berat, berlari, rugby, tennis, aerobik

high-impact, aerobik air, menari ballet, berenang cepat

Aktivitas fisik

Kode Pertanyaan Jawaban Aktivitas saat belajar / bekerja (Aktivitas termasuk kegiatan belajar, latihan, aktivitas rumah tangga, dll

P1

Apakah aktivitas sehari- hari Anda, termasuk

aktivitas berat (seperti membawa beban berat,

menggali atau pekerjaan konstruksi lain ) ?

1. Ya

2. Tidak (langsung ke P4)

P2 Berapa hari dalam seminggu Anda

melakukan aktivitas berat?

hari

P3 Berapa lama dalam sehari biasanya Anda

melakukan aktivitas berat?

Jam menit

P4

Apakah aktivitas sehari-hari Anda termasuk

aktivitas sedang yang menyebabkan

peningkatan nafas dan denyut nadi, seperti

mengangkat beban ringan dan jalan sedang

(minimal 10 menit secara kontinyu) ?

1. Ya



melakukan aktivitas sedang?

hari


melakukan aktivitas sedang ?

Jam menit

80

Perjalanan ke dan dari tempat aktivitas

Perjalanan ke tempat aktivtias, berbelanja, beribadah diluar, dll)

P7

Apakah Anda berjalan kaki atau bersepeda

untuk pergi ke suatu tempat minimal 10 menit

kontinyu ?

1. Ya



berjalan kaki atau bersepeda untuk pergi ke

suatu tempat?

hari


berjalan kaki atau bersepeda untuk pergi ke

suatu tempat?

Jam menit

Aktivitas rekreasi (Olaraga, fitnes, dan rekreasi lainnya)

P10

Apakah Anda melakukan olahraga, fitnes, atau rekreasi yang berat seperti lari, sepak bola atau rekreasi lainnya yang mengakibatkan peningkatan nafas dan denyut nadi secara besar (minimal dalam 10 menit secara kontinyu)?

1. Ya


P11

Berapa hari dalam seminggu biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong berat?

hari

P12

Berapa lama dalam sehari biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong berat?

Jam menit

P13

Apakah Anda melakukan olahraga, fitness, atau rekreasi yang tergolong sedang seperti berjalan

cepat, bersepeda, berenang, voli yang

mengakibatkan peningkatan nafas dan denyut nadi

(minimal dalam 10 menit secara kontinyu)?

1. Ya

2. Tidak (langsung ke

P16)

P14

Berapa hari dalam seminggu biasanya anda melakukan olahraga, fitnes, atau rekreasi lainnya yang tergolong sedang?

hari

P15

Berapa lama dalam sehari biasanya anda melakukan olahraga, fitness, atau rekreasi yang tergolong sedang?

Jam menit

Aktivitas menetap (Sedentary behavior) Aktivitaas yang tidak memerlukan banyak gerak seperti duduk saat bekerja, duduk saat di kendaraan, menonton televisi, atau berbaring, KECUALI tidur

P16 Berapa lama Anda duduk atau berbaring dalam sehari?

Jam menit

81

Lampiran 6. Tabulasi Data Subjek Penelitian

No Nama Sex Usia

(tahun)

BMI

(kg/m2)

Status

obesitas

Tekanan darah

terakhir

Lama

HT

(tahun)

1 RSN L 52 25.8 Ya Hipertensi derajat 1 2

2 KHSK P 55 25.8 Ya HT terkontrol 15

3 MZNR L 50 23.8 Tidak Hipertensi derajat 1 2

4 SRSP P 55 19.6 Tidak HT terkontrol 5

5 STM P 58 22.0 Tidak Hipertensi derajat 1 1

6 DJMN P 54 25.7 Ya Hipertensi derajat 1 10

7 KHST P 33 17.7 Tidak Hipertensi derajat 1 4

8 SPD L 59 25.0 Ya Hipertensi derajat 1 10

9 FDLM P 56 25.0 Ya Hipertensi derajat 1 <1

10 DYSW P 58 23.0 Tidak Hipertensi derajat 2 21

11 JMLN P 51 27.3 Ya Hipertensi derajat 2 <1

12 AMRL L 46 24.3 Tidak Hipertensi derajat 2 9

13 AGST L 49 20.1 Tidak Hipertensi derajat 2 2

14 YSPE L 32 22.5 Tidak Hipertensi derajat 2 2

15 SHRT L 47 25.4 Ya HT terkontrol <1

16 NRHS L 30 28.3 Ya Hipertensi derajat 1 <1

17 SRWH P 46 20.0 Tidak Hipertensi derajat 1 17

18 JPRY L 58 27.3 Ya Hipertensi derajat 2 5

19 SMTW L 43 22.0 Tidak Hipertensi derajat 1 <1

20 MSYD P 59 25.4 Ya Hipertensi derajat 1 <1

21 BDLS P 58 32.9 Ya HT terkontrol 10

22 HRT P 51 28.8 Ya HT terkontrol 1

23 SRRH P 51 28.5 Ya HT terkontrol 3

24 LDNR P 36 25.5 Ya Hipertensi derajat 2 2

25 BSTM L 58 18.6 Tidak Hipertensi derajat 1 13

26 WJST P 48 18.0 Tidak HT terkontrol 2

27 STRN L 48 20.6 Tidak Hipertensi derajat 1 <1

28 UMRH P 37 20.8 Tidak HT terkontrol 1

29 SDD L 59 25.21 Ya HT terkontrol 2

30 ANDP L 55 27.68 Ya HT terkontrol <1

31 IDSYR P 59 27.94 Ya Hipertensi derajat 1 26

32 STRS L 45 24.34 Tidak Hipertensi derajat 2 <1

82

No Status

DM

Lama

DM

(tahun)

Status

dislipidemia

Tingkat

aktivitas

fisik

CIMT

(mm)

Penyakit

Aterosklerosis

1 Ya 1 Ya rendah 2.22

2 Tidak 0 Tidak rendah 0.67



5 Tidak 0 Ya tinggi 0.57 PJK

6 Tidak 0 Ya rendah 1.64 PJK

7 Tidak 0 Ya rendah 0.55

8 Ya 9 Ya rendah 0.76 SNH


10 Ya 7 Ya rendah 1.01 PJK


12 Tidak 0 Ya rendah 0.70

13 Tidak 0 Ya sedang 0.72 PJK, SNH


15 Tidak 0 Ya tinggi 0.79 PJK


17 Ya <1 Tidak rendah 0.59

18 Tidak 0 Ya rendah 1.20 SNH

19 Tidak 0 Ya rendah 0.62 PJK, SNH

20 Tidak 0 Tidak sedang 0.35


22 Ya 1 Ya sedang 0.93

23 Ya 3 Ya sedang 0.65

24 Tidak 0 Ya sedang 1.03

25 Tidak 0 Tidak rendah 0.50 PJK, SNH

26 Tidak 0 Tidak sedang 0.77

27 Ya 6 Ya sedang 1.14 PJK

28 Ya <1 Tidak rendah 0.6

29 Ya 12 Tidak sedang 0.7



32 Ya 5 Ya tinggi 1.43

83

Lampiran 7. Hasil Analisis Statistik

Frequencies

Frequency Table

Jenis kelamin

15 46.9 46.9 46.9

17 53.1 53.1 100.0

32 100.0 100.0

Laki-laki

Perempuan

Total

Valid

Frequency Percent Valid Percent

Cumulative

Percent

Usia

5 15.6 15.6 15.6

8 25.0 25.0 40.6

19 59.4 59.4 100.0

32 100.0 100.0

20-39

40-49

50-59

Total

Valid


Cumulative

Percent

Obesitas

17 53.1 53.1 53.1

15 46.9 46.9 100.0

32 100.0 100.0

Ya

Tidak

Total

Valid


Cumulative

Percent

DM

16 50.0 50.0 50.0

16 50.0 50.0 100.0

32 100.0 100.0

Ya

Tidak

Total

Valid


Cumulative

Percent

Dislipidemia

22 68.8 68.8 68.8

10 31.3 31.3 100.0

32 100.0 100.0

Ya

Tidak

Total

Valid


Cumulative

Percent

Tingkat aktivitas fisik

21 65.6 65.6 65.6

8 25.0 25.0 90.6

3 9.4 9.4 100.0

32 100.0 100.0

Rendah

Sedang

Tinggi

Total

Valid


Cumulative

Percent

84

Crosstabs

Jenis kelamin * DM

Usia * DM

Crosstab

7 8 15

7.5 7.5 15.0

43.8% 50.0% 46.9%

9 8 17

8.5 8.5 17.0

56.3% 50.0% 53.1%

16 16 32

16.0 16.0 32.0

100.0% 100.0% 100.0%

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Laki-laki

Perempuan

Jenis kelamin

Total

Ya Tidak

DM

Total

Chi-Square Tests

.125b 1 .723

.000 1 1.000

.126 1 .723

1.000 .500

.122 1 .727

32

Pearson Chi-Square

Continuity Correction a

Likelihood Ratio

Fisher's Exact Test

Linear-by-Linear

Association

N of Valid Cases

Value df

Asymp. Sig.

(2-sided)

Exact Sig.

(2-sided)

Exact Sig.

(1-sided)

Computed only for a 2x2 tablea.

0 cells (.0%) have expected count less than 5. The minimum expected count is 7.

50.

b.

Crosstab

2 3 5

2.5 2.5 5.0

12.5% 18.8% 15.6%

3 5 8

4.0 4.0 8.0

18.8% 31.3% 25.0%

11 8 19

9.5 9.5 19.0

68.8% 50.0% 59.4%

16 16 32

16.0 16.0 32.0

100.0% 100.0% 100.0%

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Count

Expected Count

% within DM

20-39

40-49

50-59

Usia

Total

Ya Tidak

DM

Total

85

Mann-Whitney Test Ranks

DM N Mean Rank Sum of Ranks

Usia Ya 16 17.97 287.50

Tidak 16 15.03 240.50

Total 32

Test Statisticsa

Usia

Mann-Whitney U 104.500

Wilcoxon W 240.500

Z -1.008

Asymp. Sig. (2-tailed) .313

Exact Sig. [2*(1-tailed Sig.)] .381b

a. Grouping Variable: DM

b. Not corrected for ties.

Obesitas * DM

Chi-Square Tests

1.174a 2 .556

1.182 2 .554

.867 1 .352

32

Pearson Chi-Square

Likelihood Ratio

Linear-by-Linear

Association

N of Valid Cases

Value df

Asymp. Sig.

(2-sided)

4 cells (66.7%) have expected count less than 5. The

minimum expected count is 2.50.

a.

Crosstab

10 7 17

8.5 8.5 17.0

62.5% 43.8% 53.1%

6 9 15

7.5 7.5 15.0

37.5% 56.3% 46.9%

16 16 32

16.0 16.0 32.0

100.0% 100.0% 100.0%

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Ya

Tidak

Obesitas

Total

Ya Tidak

DM

Total

Chi-Square Tests

1.129b 1 .288

.502 1 .479

1.136 1 .286

.479 .240

1.094 1 .296

32

Pearson Chi-Square


Likelihood Ratio

Fisher's Exact Test

Linear-by-Linear

Association

N of Valid Cases

Value df

Asymp. Sig.

(2-sided)

Exact Sig.

(2-sided)

Exact Sig.

(1-sided)



50.

b.

86

Dislipidemia * DM

Tingkat aktivitas fisik * DM

Crosstab

13 9 22

11.0 11.0 22.0

81.3% 56.3% 68.8%

3 7 10

5.0 5.0 10.0

18.8% 43.8% 31.3%

16 16 32

16.0 16.0 32.0

100.0% 100.0% 100.0%

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Ya

Tidak

Dislipidemia

Total

Ya Tidak

DM

Total

Chi-Square Tests

2.327b 1 .127

1.309 1 .253

2.377 1 .123

.252 .126

2.255 1 .133

32

Pearson Chi-Square


Likelihood Ratio

Fisher's Exact Test

Linear-by-Linear

Association

N of Valid Cases

Value df

Asymp. Sig.

(2-sided)

Exact Sig.

(2-sided)

Exact Sig.

(1-sided)



00.

b.

Crosstab

11 10 21

10.5 10.5 21.0

68.8% 62.5% 65.6%

4 4 8

4.0 4.0 8.0

25.0% 25.0% 25.0%

1 2 3

1.5 1.5 3.0

6.3% 12.5% 9.4%

16 16 32

16.0 16.0 32.0

100.0% 100.0% 100.0%

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Count

Expected Count

% within DM

Rendah

Sedang

Tinggi

Tingkat

aktivitas

fisik

Total

Ya Tidak

DM

Total

Chi-Square Tests

.381a 2 .827

.387 2 .824

.279 1 .597

32

Pearson Chi-Square

Likelihood Ratio

Linear-by-Linear

Association

N of Valid Cases

Value df

Asymp. Sig.

(2-sided)

4 cells (66.7%) have expected count less than 5. The

minimum expected count is 1.50.

a.

87



Tingkat aktivitas fisik Ya 16 15.88 254.00

Tidak 16 17.13 274.00

Total 32

Test Statisticsa

Tingkat aktivitas

fisik


Wilcoxon W 254.000

Z -.450





Riwayat merokok*DM Riwayat merokok * DM Crosstabulation

DM

Total Ya Tidak

Riwayat merokok Ya Count 5 8 13

% within Riwayat merokok 38.5% 61.5% 100.0%

Tidak Count 11 8 19


Total Count 16 16 32


Chi-Square Tests

Value df

Asymptotic Significance

(2-sided) Exact Sig. (2-

sided) Exact Sig. (1-

sided)

Pearson Chi-Square 1.166a 1 .280

Continuity Correctionb .518 1 .472

Likelihood Ratio 1.174 1 .279 Fisher's Exact Test .473 .236

Linear-by-Linear Association

1.130 1 .288

N of Valid Cases 32 a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 6.50.

b. Computed only for a 2x2 table

Derajat hipertensi*DM Derajat hipertensi * DM Crosstabulation

DM

Total Ya Tidak

Derajat hipertensi HT derajat 2 Count 3 5 8

% within Derajat hipertensi 37.5% 62.5% 100.0%

HT derajat 1 Count 6 8 14


88

HT terkontrol Count 7 3 10




Chi-Square Tests

Value Df

Asymptotic Significance (2-

sided)

Pearson Chi-Square 2.386a 2 .303

Likelihood Ratio 2.438 2 .296 N of Valid Cases 32 a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 4.00.



Derajat hipertensi Ya 16 18.69 299.00

Tidak 16 14.31 229.00

Total 32

Test Statisticsa

Derajat hipertensi


Wilcoxon W 229.000

Z -1.413





Lama hipertensi*DM Lama hipertensi * DM Crosstabulation

DM

Total Ya Tidak

Lama hipertensi <5 tahun Count 10 11 21

% within Lama hipertensi 47.6% 52.4% 100.0%

5-10 tahun Count 3 3 6


>10 tahun Count 3 2 5




Chi-Square Tests

Value df

Asymptotic

Significance (2-

sided)

Pearson Chi-Square .248a 2 .884

Likelihood Ratio .249 2 .883

Linear-by-Linear Association .215 1 .643

N of Valid Cases 32

a. 4 cells (66.7%) have

expected count less than

5. The minimum

expected count is 2.50.

89



Lama hipertensi Ya 16 17.09 273.50

Tidak 16 15.91 254.50

Total 32

Test Statisticsa

Lama hipertensi


Wilcoxon W 254.500

Z -.426





Explore Jenis Kelamin-CIMT (DM - Non DM)

Case Summaries

CIMT

DM Jenis kelamin N Mean Std. Deviation Median Minimum Maximum

Ya Laki-laki 7 1.1400 .56654 1.1400 .56 2.22

Perempuan 9 .7944 .21967 .8000 .51 1.15

Total 16 .9456 .43066 .8550 .51 2.22

Tidak Laki-laki 8 .7150 .25219 .7100 .35 1.20

Perempuan 8 .7900 .39587 .7050 .35 1.64

Total 16 .7525 .32298 .7100 .35 1.64

Total Laki-laki 15 .9133 .46639 .7600 .35 2.22

Perempuan 17 .7924 .30446 .7400 .35 1.64

Total 32 .8491 .38709 .7500 .35 2.22

Explore Usia-CIMT (DM – Non DM)

Case Summaries

CIMT

DM Usia N Mean Std. Deviation Median Minimum Maximum

Ya 20-39 2 .5800 .02828 .5800 .56 .60

40-49 3 1.0533 .42665 1.1400 .59 1.43

50-59 11 .9827 .45824 .9100 .51 2.22

Total 16 .9456 .43066 .8550 .51 2.22

Tidak 20-39 3 .8067 .24173 .8400 .55 1.03

40-49 5 .7200 .06671 .7200 .62 .79

50-59 8 .7525 .44975 .6200 .35 1.64

Total 16 .7525 .32298 .7100 .35 1.64

Total 20-39 5 .7160 .21173 .6000 .55 1.03

40-49 8 .8450 .29037 .7450 .59 1.43

50-59 19 .8858 .45712 .7600 .35 2.22

Total 32 .8491 .38709 .7500 .35 2.22

90

Explore Obesitas-CIMT (DM)

Case Summaries

CIMT DM Obesitas N Mean Std. Deviation Median Minimum Maximum

Ya Ya 10 .9560 .49858 .8350 .51 2.22

Tidak 6 .9283 .32921 .9050 .59 1.43

Total 16 .9456 .43066 .8550 .51 2.22

Tidak Ya 7 .9171 .41744 .7900 .35 1.64

Tidak 9 .6244 .15076 .6200 .35 .84

Total 16 .7525 .32298 .7100 .35 1.64

Total Ya 17 .9400 .45339 .7900 .35 2.22

Tidak 15 .7460 .27466 .7000 .35 1.43

Total 32 .8491 .38709 .7500 .35 2.22

Explore Dislipidemia-CIMT (DM – Non DM)

Case Summaries

CIMT

DM Dislipidemia N Mean Std. Deviation Median Minimum Maximum

Ya Ya 13 1.0185 .44784 .9300 .51 2.22

Tidak 3 .6300 .06083 .6000 .59 .70

Total 16 .9456 .43066 .8550 .51 2.22

Tidak Ya 9 .8689 .36057 .7200 .55 1.64

Tidak 7 .6029 .20246 .6700 .35 .84

Total 16 .7525 .32298 .7100 .35 1.64

Total Ya 22 .9573 .41207 .8550 .51 2.22

Tidak 10 .6110 .16829 .6350 .35 .84

Total 32 .8491 .38709 .7500 .35 2.22

Explore Tingkat aktivitas fisik-CIMT (DM – Non DM)

Case Summaries

CIMT

DM

Tingkat aktivitas

fisik N Mean

Std.

Deviation Median Minimum Maximum

Ya Rendah 11 .9345 .48583 .8000 .51 2.22

Sedang 4 .8550 .22576 .8150 .65 1.14

Tinggi 1 1.4300 . 1.4300 1.43 1.43

Total 16 .9456 .43066 .8550 .51 2.22

Tidak Rendah 10 .7810 .37734 .6850 .35 1.64

Sedang 4 .7175 .28016 .7450 .35 1.03

Tinggi 2 .6800 .15556 .6800 .57 .79

Total 16 .7525 .32298 .7100 .35 1.64

Total Rendah 21 .8614 .43389 .7400 .35 2.22

Sedang 8 .7863 .24675 .7450 .35 1.14

Tinggi 3 .9300 .44677 .7900 .57 1.43

Total 32 .8491 .38709 .7500 .35 2.22

91

Explore

Riwayat merokok-CIMT (DM-Non DM)

Case Summaries

CIMT

DM Riwayat merokok N Mean Std. Deviation Median Minimum Maximum

Ya Ya 5 1.3040 .60277 1.1700 .56 2.22

Tidak 11 .7827 .19865 .7600 .51 1.15

Total 16 .9456 .43066 .8550 .51 2.22

Tidak Ya 8 .7150 .25219 .7100 .35 1.20

Tidak 8 .7900 .39587 .7050 .35 1.64

Total 16 .7525 .32298 .7100 .35 1.64

Total Ya 13 .9415 .49716 .7900 .35 2.22

Tidak 19 .7858 .28789 .7400 .35 1.64

Total 32 .8491 .38709 .7500 .35 2.22

Explore DM-CIMT

Case Summaries

CIMT

16 .9456 .43066 .8550 .51 2.22

16 .7525 .32298 .7100 .35 1.64

32 .8491 .38709 .7500 .35 2.22

DM

Ya

Tidak

Total

N Mean Std. Deviation Median Minimum Maximum

Tests of Normality

.828 16 .007

.880 16 .038

DM

Ya

Tidak

CIMT

Statistic df Sig.

Shapiro-Wilk

Lilliefors Significance Correctiona.

92

NPar Tests Mann-Whitney Test

Jenis kelamin (Keseluruhan) Explore

Tests of Normality

Jenis kelamin

Kolmogorov-Smirnova Shapiro-Wilk

Statistic df Sig. Statistic df Sig.

CIMT Laki-laki .229 15 .033 .850 15 .017

Perempuan .137 17 .200* .908 17 .092

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction


Ranks

Jenis kelamin N Mean Rank Sum of Ranks

CIMT Laki-laki 15 17.63 264.50

Perempuan 17 15.50 263.50

Total 32

Ranks

16 18.78 300.50

16 14.22 227.50

32

DM

Ya

Tidak

Total

CIMT

N Mean Rank Sum of Ranks

Test Statisticsb

91.500

227.500

-1.376

.169

.171a

Mann-Whitney U

Wilcoxon W

Z

Asymp. Sig. (2-tailed)

Exact Sig. [2*(1-tailed

Sig.)]

CIMT

Not corrected for ties.a.

Grouping Variable: DMb.

93

Usia (Keseluruhan)

Explore Tests of Normality

Usia



CIMT 20-39 .308 5 .136 .834 5 .148

40-49 .325 8 .013 .810 8 .036

50-59 .153 19 .200* .872 19 .016



NPar Tests Kruskal-Wallis Test

Obesitas (Keseluruhan)


Obesitas



CIMT Ya .166 17 .200* .872 17 .024

Tidak .166 15 .200* .911 15 .141



94


Ranks

Obesitas N

Mean

Rank

Sum of

Ranks

CIMT Ya 17 18.65 317.00

Tidak 15 14.07 211.00

Total 32

Dislipidemi (Keseluruhan)

Explore

Tests of Normality

Dislipidemia



CIMT Ya .149 22 .200* .865 22 .006

Tidak .150 10 .200* .931 10 .454



95


Ranks

Dislipidemia N

Mean

Rank

Sum of

Ranks

CIMT Ya 22 19.30 424.50

Tidak 10 10.35 103.50

Total 32

Tingkat aktivitas fisik (Keseluruhan)


Tingkat aktivitas fisik



CIMT Rendah .186 21 .055 .826 21 .002

Sedang .165 8 .200* .965 8 .856

Tinggi .290 3 . .926 3 .475



96

NPar Tests Kruskal-Wallis Test

Riwayat merokok (Keseluruhan)


Riwayat merokok



CIMT Ya .196 13 .182 .879 13 .069

Tidak .165 19 .189 .898 19 .045


97


Ranks

Riwayat

merokok N

Mean

Rank

Sum of

Ranks

CIMT Ya 13 18.00 234.00

Tidak 19 15.47 294.00

Total 32

98

Lampiran 8. Dokumentasi Penelitian

Penjelasan penelitian dan wawancara oleh penulis

Pengambilan data CIMT

99

Lampiran 9.

BIODATA MAHASISWA

Identitas

Nama : Mutiara Chairsabella

NIM : 22010112130070

Tempat/Tanggal Lahir: Semarang, 5 September 1994

Jenis Kelamin : Perempuan

Alamat : Jl. Wamena Raya D.194/195 Beji, Ungaran

No. Handphone : 081321347312

Email : [email protected]

Riwayat Pendidikan Formal

1. SD : SDIT Assalamah Ungaran Lulus tahun: 2006

2. SMP : SMP Semesta Semarang Lulus tahun: 2009

3. SMA : SMA Semesta Semarang Lulus tahun: 2012

4. S1 : Fakultas Kedokteran Universitas Diponegoro Masuk tahun: 2012

Keanggotaan Organisasi

1. Bidang Hubungan Luar HIMA KU Undip tahun 2013 s/d 2014

2. AMSA Undip tahun 2013 s/d 2014

Publikasi Ilmiah

1. Mutiara Chairsabella, Valensa Yosephi, Yustina Wahyuningtiyas, Kis

Djamiatun. Vaksin Vektor Virus Penguat BCG Sebagai Upaya Eliminasi

Tuberkulosis (TB). JIMKI, 2016, Volume 4, Nomor 1, Halaman 24-34

Prestasi

1. Medali perunggu SIMPIC Faculty of Medicine Mahidol University 2015

2. Medali perunggu II AVSQ AMSW FK Unair 2015

DAFTAR PUSTAKA - Institutional Repository Undip (Undip …eprints.undip.ac.id/50731/8/Mutiara_Chairsabella_22010112130070... · 26. Antono D, Hamonangani R. Penyakit Arteri Perifer.

Documents